French study on outcomes in HR+/HER2- early breast cancer patients with Oncotype DX
Part of Cancer, Skin clinical trials.
This study looks at how well treatments work for people with early-stage, hormone receptor-positive, HER2-negative breast cancer when the Oncotype DX test helps guide therapy. It aims to understand real-world outcomes in French patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have early-stage breast cancer that can be removed with surgery
- Your breast cancer is hormone receptor-positive (HR+) and HER2-negative
- You have had an Oncotype DX test on your tumor sample
- You have not had chemotherapy or hormone therapy before surgery
- You do not have cancer in more than 4 lymph nodes, distant spread, or another cancer in the past 10 years
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special type of mammogram with contrast dye to see if it can predict how well breast cancer responds to chemotherapy before surgery. It's for people with HER2-positive or triple-negative breast cancer.
This study looks at young women with early-stage breast cancer who are premenopausal (still having periods) and have a low-to-intermediate Oncotype score, to see how well hormone therapy works. It aims to understand if current treatment decisions are appropriate.
This study looks at how people feel (patient-reported outcomes) and their real-world health data while they receive trastuzumab deruxtecan for advanced HER2-positive, HER2-low, or HER2-ultralow breast cancer. It helps researchers understand what outcomes happen outside of tightly controlled clinical trials.
This study looks at the potential harms and benefits of hormone (endocrine) therapy in people age 70 and older with early-stage, hormone-receptor–positive breast cancer. It may help doctors choose which hormone treatment approach is safest and most helpful for older patients.
This study tests different treatment plans given before surgery for early breast cancer that is both hormone receptor-positive and HER2-positive. The goal is to see which treatment is more effective and to tailor it to each patient.
This study looks at the genetic details of HER2-positive breast cancer to help find subtypes and improve future treatments. It does not test a new drug but collects information from your tumor tissue to learn more about the disease.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.